ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Monday, November 13, 2023

9:00AM-11:00AM: Abstract Number: 1550

Importance of Shared Decision-Making for Patients with ANCA-Associated Vasculitis

(1534–1553) Vasculitis – ANCA-Associated Poster II: Epidemiology, Outcomes, & Classification

9:00AM-11:00AM: Abstract Number: 1038

Improved Assessment of Structural Damage in the Spine in Patients with Axial Spondyloarthritis by MRI-based Synthetic CT: A Comparison with Low-dose CT and X-ray

(1033–1051) Imaging of Rheumatic Diseases Poster I

9:00AM-11:00AM: Abstract Number: 1090

Improved Patient and Team Satisfaction and Pharmacy Outcomes After Implementing a Rheumatology Clinical Pharmacist in a Large Academic Medical Center

(1082–1099) Measures & Measurement of Healthcare Quality Poster I

9:00AM-11:00AM: Abstract Number: 1232

Improvement Across Organ System, Physician and Patient Reported Outcome Measures over a 36-time Period in the Juvenile Systemic Scleroderma Inception Cohort

(1221–1255) Pediatric Rheumatology – Clinical Poster II: Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 1416

Improvement of Work Absenteeism Following Start of Methotrexate Monotherapy in Newly-Diagnosed Psoriatic Arthritis

(1412–1441) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II: SpA

9:00AM-11:00AM: Abstract Number: 1412

Improvements in Patient-Reported Outcomes Through 6 Months of Guselkumab Treatment in Patients with Active Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry

(1412–1441) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II: SpA

9:00AM-11:00AM: Abstract Number: 1099

Improving Hydroxychloroquine Dosing and Eye Screening Compliance in Patients with Connective Tissue Disorder

(1082–1099) Measures & Measurement of Healthcare Quality Poster I

9:00AM-11:00AM: Abstract Number: 1088

Improving JIA Outcomes Assessments in a Large Pediatric Rheumatology Practice: A Fellow Quality Improvement Project

(1082–1099) Measures & Measurement of Healthcare Quality Poster I

9:00AM-11:00AM: Abstract Number: 1098

Improving Osteoporosis Screening in Patients with Polymyalgia Rheumatica and Giant Cell Arteritis

(1082–1099) Measures & Measurement of Healthcare Quality Poster I

9:00AM-11:00AM: Abstract Number: 1089

Improving Recombinant Zoster Vaccination Rates Among Immunosuppressed Veterans in an Academic Rheumatology Clinic

(1082–1099) Measures & Measurement of Healthcare Quality Poster I

9:00AM-11:00AM: Abstract Number: 1362

Improving Reproductive Health Counseling for Pediatric Adolescent Females Prescribed Teratogenic DMARDs

(1345–1364) Reproductive Issues in Rheumatic Disorders Poster II

9:00AM-11:00AM: Abstract Number: 1092

Improving Screening of Lupus Nephritis in Patients with Systemic Lupus Erythematous

(1082–1099) Measures & Measurement of Healthcare Quality Poster I

9:00AM-11:00AM: Abstract Number: 1392

Improving the Diagnostic Accuracy in Axial Spondyloarthritis: Interim Results of a Nationwide Telemedicine Project

(1383–1411) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II: Imaging & AS

9:00AM-11:00AM: Abstract Number: 1097

Improving Vaccine Uptake of the Pneumococcal 20-valent Conjugate Vaccine (PCV20) in Young Rheumatic Disease Patients Using a Brief Intense Partnership Program

(1082–1099) Measures & Measurement of Healthcare Quality Poster I

9:00AM-11:00AM: Abstract Number: 0912

Inadequate Screening for Antiphospholipid Syndrome with Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus

(0899–0933) SLE – Etiology & Pathogenesis Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].